Aspira Women's Health Files S-1/A Update

TL;DR

Aspira Women's Health (AWH) filed an S-1/A on 2/11/25. Check financials for Q3 2024.

AI Summary

Aspira Women's Health Inc. filed an S-1/A on February 11, 2025, to update its registration statement. The company, formerly known as Vermillion, Inc., is in the in vitro & in vivo diagnostic substances industry and is based in Austin, TX. The filing includes financial data for periods ending September 30, 2024, and December 31, 2023, and 2022.

Why It Matters

This S-1/A filing provides updated information for investors and the market regarding Aspira Women's Health's financial status and corporate actions.

Risk Assessment

Risk Level: medium — S-1/A filings often indicate potential stock offerings or significant corporate changes, which carry inherent investment risks.

Key Numbers

• 2024-09-30 — Financial Reporting Period End (Latest reported quarter)
• 2023-12-31 — Financial Reporting Period End (Previous fiscal year end)
• 2022-12-31 — Financial Reporting Period End (Prior fiscal year end)

Key Players & Entities

• Aspira Women's Health Inc. (company) — Filer
• 0000926617 (company) — Central Index Key
• VERMILLION, INC. (company) — Former Company Name
• CIPHERGEN BIOSYSTEMS INC (company) — Former Company Name
• ABIOTIC SYSTEMS (company) — Former Company Name
• 20250211 (date) — Filing Date
• 2024-09-30 (date) — Financial Period End
• 2023-12-31 (date) — Financial Period End
• 2022-12-31 (date) — Financial Period End

FAQ

Key Financial Figures

• $0.40 — at an assumed public offering price of $0.40 per Unit, the last reported sale price
• $0.001 — d to the public in this offering, minus $0.001. Each Warrant will entitle the holder

Filing Documents

• forms-1a.htm (S-1/A) — 3225KB
• ex1-1.htm (EX-1.1) — 482KB
• ex4-10.htm (EX-4.10) — 118KB
• ex4-11.htm (EX-4.11) — 88KB
• ex4-12.htm (EX-4.12) — 115KB
• ex4-13.htm (EX-4.13) — 125KB
• ex5-1.htm (EX-5.1) — 26KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 27KB
• forms-1a_001.jpg (GRAPHIC) — 28KB
• ex5-1_001.jpg (GRAPHIC) — 3KB
• 0001493152-25-005769.txt ( ) — 13006KB
• awh-20240930.xsd (EX-101.SCH) — 66KB
• awh-20240930_cal.xml (EX-101.CAL) — 71KB
• awh-20240930_def.xml (EX-101.DEF) — 353KB
• awh-20240930_lab.xml (EX-101.LAB) — 524KB
• awh-20240930_pre.xml (EX-101.PRE) — 434KB
• forms-1a_htm.xml (XML) — 1800KB

Underwriting

Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the public offering price payable to the representative of the underwriters. See "Underwriting" beginning on page 99 for additional information regarding underwriters' compensation. We have granted a 45-day option to the underwriters to purchase up to 7,500,000 additional shares of common stock and/or up to 7,500,000 Pre-funded warrants and/or up to 7,500,000 Warrants solely to cover over-allotments or any combination thereof, if any. The underwriters expect to deliver the securities to purchasers on or about , 2025. ThinkEquity The date of this prospectus is , 2025 TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS 1 INFORMATION REGARDING FORWARD-LOOKING STATEMENTS 2 PROSPECTUS SUMMARY 5 THE OFFERING 12 RISK FACTORS 14 USE OF PROCEEDS 33 CAPITALIZATION 34

DILUTION

DILUTION 35 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 37

BUSINESS

BUSINESS 55 MANAGEMENT 75 EXECUTIVE AND DIRECTOR COMPENSATION 78 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 88 PRINCIPAL STOCKHOLDERS 89 DESCRIPTION OF CAPITAL STOCK AND SECURITIES WE ARE OFFERING 90 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS 94

UNDERWRITING

UNDERWRITING 99 LEGAL MATTERS 104 EXPERTS 104 WHERE YOU CAN FIND MORE INFORMATION 104 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS You should carefully read this prospectus before deciding to invest in our securities. Neither we nor the underwriters have authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the Securities and Exchange Commission (the "SEC"). We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The underwriters are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information provided in this prospectus contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. We obtained the industry and market data in this prospectus from our own research as well as from industry and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the industry in which we operate that are subject to a high degree of uncertainty, including those discussed in "Risk Factors." We caution you not to give undue weight to such projections, assumptions, and estimates. Further, industry and general publications, studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do

View Full Filing

View this S-1/A filing on SEC EDGAR